



**Merck & Co., Inc.
Financial Highlights Package
Third Quarter 2011
Table of Contents**

| | |
|--|----|
| Table 1: GAAP P&L..... | 1 |
| Table 1a: GAAP P&L - Current Year and Prior Year by Quarter..... | 2 |
| Table 2a: GAAP to Non-GAAP P&L Reconciliation 3Q11 | 3 |
| Table 2b: GAAP to Non-GAAP P&L Reconciliation Sep YTD 11 | 4 |
| Table 2c: GAAP to Non-GAAP P&L Reconciliation 3Q10 | 5 |
| Table 2d: GAAP to Non-GAAP P&L Reconciliation Sep YTD 10..... | 6 |
| Table 3: Sales - Current Year and Prior Year by Quarter | 7 |
| Table 3a: Sales - U.S. / Ex- U.S. 3Q11 | 8 |
| Table 3b: Sales - U.S. / Ex- U.S. Sep YTD 11 | 9 |
| Table 3c: Sales - Pharmaceutical Geographic Split..... | 10 |
| Table 4: Equity Income / JV Sales / Other (Income) Expense..... | 11 |

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1

| | GAAP | | % Change | GAAP | | % Change |
|--|-----------|-----------|----------|--------------|--------------|----------|
| | 3Q11 | 3Q10 | | Sep YTD 2011 | Sep YTD 2010 | |
| Sales | \$ 12,022 | \$ 11,125 | 8% | \$ 35,753 | \$ 33,893 | 5% |
| Costs, Expenses and Other | | | | | | |
| Materials and production ⁽¹⁾ | 4,352 | 4,191 | 4% | 12,695 | 13,956 | -9% |
| Marketing and administrative ^{(1) / (2)} | 3,340 | 3,192 | 5% | 10,029 | 9,589 | 5% |
| Research and development ^{(1) / (2)} | 1,954 | 2,322 | -16% | 6,048 | 6,552 | -8% |
| Restructuring costs ⁽³⁾ | 119 | 50 | * | 773 | 864 | -11% |
| Equity income from affiliates ⁽⁴⁾ | (161) | (236) | -32% | (354) | (417) | -15% |
| Other (income) expense, net ^{(1) / (5)} | 66 | 1,108 | -94% | 809 | 995 | -19% |
| Income Before Taxes | 2,352 | 498 | * | 5,753 | 2,354 | * |
| Income Tax Provision | 628 | 126 | | 904 | 872 | |
| Net Income | 1,724 | 372 | * | 4,849 | 1,482 | * |
| Less: Net Income Attributable to Noncontrolling Interests | 32 | 30 | | 89 | 89 | |
| Net Income Attributable to Merck & Co., Inc. | \$ 1,692 | \$ 342 | * | \$ 4,760 | \$ 1,393 | * |
| Earnings per Common Share Assuming Dilution ⁽⁶⁾ | \$ 0.55 | \$ 0.11 | * | \$ 1.53 | \$ 0.44 | * |
| Average Shares Outstanding Assuming Dilution | 3,091 | 3,102 | | 3,102 | 3,123 | |
| Tax Rate ⁽⁷⁾ | 26.7% | 25.3% | | 15.7% | 37.1% | |

* \geq 100%

(1) Amounts include the impact of acquisition-related costs and restructuring costs. See accompanying tables for details.

(2) The third quarter and first nine months of 2010 include a reclassification of certain expenses from marketing and administrative to research and development of \$26 million and \$78 million, respectively.

(3) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.

(4) Primarily reflects equity income from the AstraZeneca LP, Johnson & Johnson[®]Merck Consumer Pharmaceuticals Company ("JJMCP"), and Sanofi Pasteur MSD partnerships. In the third quarter of 2011, the company divested its interest in the JJMCP joint venture.

(5) Other (income) expense, net in the third quarter and first nine months of 2011 includes a \$136 million gain on the sale of the company's interest in the JJMCP joint venture. In addition, other (income) expense, net in the first nine months of 2011 includes a charge of \$500 million related to the resolution of the arbitration proceeding with Johnson & Johnson and a \$127 million gain on the sale of certain manufacturing facilities and related assets. Other (income) expense, net in the third quarter and first nine months of 2010 includes a \$950 million legal reserve. In addition, other (income) expense, net in the first nine months of 2010 reflects \$443 million of income recognized upon AstraZeneca's asset option exercise and \$102 million of income on the settlement of certain disputed royalties.

(6) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate earnings per common share assuming dilution was \$1,689 million and \$340 million for the third quarter of 2011 and 2010, respectively, and was \$4,748 million and \$1,387 million for the first nine months of 2011 and 2010, respectively.

(7) The GAAP effective tax rate for the third quarter of 2011 was 26.7%. The GAAP effective tax rate for the first nine months of 2011 was 15.7%, which reflects the net favorable impact of approximately \$700 million related to the settlement of the company's 2002-2005 federal income tax audit. Excluding this item and the other non-GAAP reconciling items detailed in the accompanying tables, the effective tax rates were 23.7% and 24.5% for the third quarter and first nine months of 2011, respectively. The GAAP effective tax rates for the third quarter and first nine months of 2010 were 25.3% and 37.1%, respectively. Excluding the impact of the non-GAAP reconciling items detailed in the accompanying tables, the effective tax rates were 22.2% and 21.9% for the third quarter and first nine months of 2010, respectively.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1a

| | 2011 | | | | 2010 | | | | | | % Change | |
|---|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|---------|
| | 1Q | 2Q | 3Q | Sep YTD | 1Q | 2Q | 3Q | Sep YTD | 4Q | Full Year | 3Q | Sep YTD |
| Sales | \$ 11,580 | \$ 12,151 | \$ 12,022 | \$ 35,753 | \$ 11,422 | \$ 11,346 | \$ 11,125 | \$ 33,893 | \$ 12,094 | \$ 45,987 | 8% | 5% |
| Costs, Expenses and Other | | | | | | | | | | | | |
| Materials and production | 4,059 | 4,284 | 4,352 | 12,695 | 5,216 | 4,549 | 4,191 | 13,956 | 4,440 | 18,396 | 4% | -9% |
| Marketing and administrative ⁽¹⁾ | 3,164 | 3,525 | 3,340 | 10,029 | 3,222 | 3,175 | 3,192 | 9,589 | 3,537 | 13,125 | 5% | 5% |
| Research and development ⁽¹⁾ | 2,158 | 1,936 | 1,954 | 6,048 | 2,051 | 2,179 | 2,322 | 6,552 | 4,559 | 11,111 | -16% | -8% |
| Restructuring costs | (14) | 668 | 119 | 773 | 288 | 526 | 50 | 864 | 121 | 985 | * | -11% |
| Equity income from affiliates | (138) | (55) | (161) | (354) | (138) | (43) | (236) | (417) | (171) | (587) | -32% | -15% |
| Other (income) expense, net | 622 | 121 | 66 | 809 | 167 | (281) | 1,108 | 995 | 309 | 1,304 | -94% | -19% |
| Income (Loss) Before Taxes | 1,729 | 1,672 | 2,352 | 5,753 | 616 | 1,241 | 498 | 2,354 | (701) | 1,653 | * | * |
| Income Tax Provision (Benefit) | 658 | (382) | 628 | 904 | 286 | 461 | 126 | 872 | (201) | 671 | | |
| Net Income (Loss) | 1,071 | 2,054 | 1,724 | 4,849 | 330 | 780 | 372 | 1,482 | (500) | 982 | * | * |
| Less: Net Income Attributable to Noncontrolling Interests | 28 | 30 | 32 | 89 | 31 | 28 | 30 | 89 | 31 | 121 | | |
| Net Income (Loss) Attributable to Merck & Co., Inc. | \$ 1,043 | \$ 2,024 | \$ 1,692 | \$ 4,760 | \$ 299 | \$ 752 | \$ 342 | \$ 1,393 | \$ (531) | \$ 861 | * | * |
| Earnings (Loss) per Common Share Assuming Dilution | \$ 0.34 | \$ 0.65 | \$ 0.55 | \$ 1.53 | \$ 0.09 | \$ 0.24 | \$ 0.11 | \$ 0.44 | \$ (0.17) | \$ 0.28 | * | * |
| Average Shares Outstanding Assuming Dilution | 3,104 | 3,110 | 3,091 | 3,102 | 3,141 | 3,125 | 3,102 | 3,123 | 3,081 | 3,120 | | |
| Tax Rate | 38.1% | -22.8% | 26.7% | 15.7% | 46.4% | 37.1% | 25.3% | 37.1% | 28.7% | 40.6% | | |

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

* ≥ 100%

(1) Amounts in 2010 include a reclassification of certain expenses from marketing and administrative to research and development of \$24 million, \$28 million, \$26 million, \$42 million and \$120 million in 1Q, 2Q, 3Q, 4Q and full year, respectively.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
THIRD QUARTER 2011
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a

| | GAAP | Acquisition- Related Costs ⁽¹⁾ | Restructuring Costs ⁽²⁾ | Certain Other Items ⁽³⁾ | Adjustment Subtotal | Non-GAAP |
|--|-----------|--|---------------------------------------|---------------------------------------|------------------------|------------------------|
| Sales | \$ 12,022 | | | | \$ - | \$ 12,022 |
| Materials and production | 4,352 | 1,284 | 99 | | 1,383 | 2,969 |
| Marketing and administrative | 3,340 | 57 | 31 | | 88 | 3,252 |
| Research and development | 1,954 | 22 | 28 | | 50 | 1,904 |
| Restructuring costs | 119 | | 119 | | 119 | - |
| Equity income from affiliates | (161) | | | | - | (161) |
| Other (income) expense, net | 66 | | | (137) | (137) | 203 |
| Income Before Taxes | 2,352 | (1,363) | (277) | 137 | (1,503) | 3,855 |
| Taxes on Income | 628 | | | | (287) ⁽⁴⁾ | 915 |
| Net Income | 1,724 | | | | (1,216) | 2,940 |
| Less: Net Income Attributable to Noncontrolling Interests | 32 | | | | - | 32 |
| Net Income Attributable to Merck & Co., Inc. | \$ 1,692 | | | | \$ (1,216) | \$ 2,908 |
| Earnings per Common Share Assuming Dilution | \$ 0.55 | | | | | \$ 0.94 ⁽⁵⁾ |
| Average Shares Outstanding Assuming Dilution | 3,091 | | | | | 3,091 |
| Tax Rate | 26.7% | | | | | 23.7% |

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company's formal restructuring programs. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Reflects the gain on the divestiture of the company's interest in the Johnson & Johnson[®]Merck Consumer Pharmaceuticals Company joint venture.

(4) Represent the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$2,903 million for the third quarter of 2011.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
NINE MONTHS ENDED SEPTEMBER 30, 2011
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b

| | GAAP | Acquisition- Related Costs ⁽¹⁾ | Restructuring Costs ⁽²⁾ | Certain Other Items ⁽³⁾ | Adjustment Subtotal | Non-GAAP |
|--|-----------|--|---------------------------------------|---------------------------------------|------------------------|------------------------|
| Sales | \$ 35,753 | | | | \$ - | \$ 35,753 |
| Materials and production | 12,695 | 3,925 | 280 | | 4,205 | 8,490 |
| Marketing and administrative | 10,029 | 192 | 77 | | 269 | 9,760 |
| Research and development | 6,048 | 343 | 89 | | 432 | 5,616 |
| Restructuring costs | 773 | | 773 | | 773 | - |
| Equity income from affiliates | (354) | | | | - | (354) |
| Other (income) expense, net | 809 | | | 236 | 236 | 573 |
| Income Before Taxes | 5,753 | (4,460) | (1,219) | (236) | (5,915) | 11,668 |
| Taxes on Income | 904 | | | | (1,955) ⁽⁴⁾ | 2,859 |
| Net Income | 4,849 | | | | (3,960) | 8,809 |
| Less: Net Income Attributable to Noncontrolling Interests | 89 | | | | - | 89 |
| Net Income Attributable to Merck & Co., Inc. | \$ 4,760 | | | | \$ (3,960) | \$ 8,720 |
| Earnings per Common Share Assuming Dilution | \$ 1.53 | | | | | \$ 2.80 ⁽⁵⁾ |
| Average Shares Outstanding Assuming Dilution | 3,102 | | | | | 3,102 |
| Tax Rate | 15.7% | | | | | 24.5% |

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$3.8 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as \$118 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company's formal restructuring programs. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Included in other (income) expense, net is a \$500 million charge related to the resolution of the arbitration proceeding with Johnson & Johnson, a \$136 million gain on the divestiture of the company's interest in the Johnson & Johnson[®]Merck Consumer Pharmaceuticals Company joint venture, as well as a \$127 million gain on the sale of certain manufacturing facilities and related assets.

(4) Includes a net benefit of approximately \$700 million relating to the settlement of the company's 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net \$230 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$8,697 million for the first nine months of 2011.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
THIRD QUARTER 2010
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2c

| | GAAP | Acquisition- Related Costs ⁽¹⁾ | Restructuring Costs ⁽²⁾ | Certain Other Items ⁽³⁾ | Adjustment Subtotal | Non-GAAP |
|--|-----------|--|---------------------------------------|---------------------------------------|------------------------|------------------------|
| Sales | \$ 11,125 | | | | \$ - | \$ 11,125 |
| Materials and production | 4,191 | 1,351 | 44 | | 1,395 | 2,796 |
| Marketing and administrative | 3,192 | 64 | 130 | | 194 | 2,998 |
| Research and development | 2,322 | 189 | 163 | | 352 | 1,970 |
| Restructuring costs | 50 | | 50 | | 50 | - |
| Equity income from affiliates | (236) | | | | - | (236) |
| Other (income) expense, net | 1,108 | | | 950 | 950 | 158 |
| Income Before Taxes | 498 | (1,604) | (387) | (950) | (2,941) | 3,439 |
| Taxes on Income | 126 | | | | (638) ⁽⁴⁾ | 764 |
| Net Income | 372 | | | | (2,303) | 2,675 |
| Less: Net Income Attributable to Noncontrolling Interests | 30 | | | | - | 30 |
| Net Income Attributable to Merck & Co., Inc. | \$ 342 | | | | \$ (2,303) | \$ 2,645 |
| Earnings per Common Share Assuming Dilution | \$ 0.11 | | | | | \$ 0.85 ⁽⁵⁾ |
| Average Shares Outstanding Assuming Dilution | 3,102 | | | | | 3,102 |
| Tax Rate | 25.3% | | | | | 22.2% |

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in marketing and administrative expenses reflect transaction and integration costs associated with mergers and acquisitions. Amounts included in research and development expense represent in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be sold or closed related to actions under the company's formal restructuring programs.

(3) Included in other (income) expense, net is a \$950 million legal reserve.

(4) Includes a \$380 million tax benefit from changes in a foreign entity's tax rate, as well as the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$2,635 million for the third quarter of 2010.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
NINE MONTHS ENDED SEPTEMBER 30, 2010
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2d

| | GAAP | Acquisition- Related Costs ⁽¹⁾ | Restructuring Costs ⁽²⁾ | Certain Other Items ⁽³⁾ | Adjustment Subtotal | Non-GAAP |
|--|-----------|--|---------------------------------------|---------------------------------------|------------------------|------------------------|
| Sales | \$ 33,893 | | | | \$ - | \$ 33,893 |
| Materials and production | 13,956 | 5,360 | 325 | | 5,685 | 8,271 |
| Marketing and administrative | 9,589 | 219 | 130 | | 349 | 9,240 |
| Research and development | 6,552 | 216 | 313 | | 529 | 6,023 |
| Restructuring costs | 864 | | 864 | | 864 | - |
| Equity income from affiliates | (417) | | | | - | (417) |
| Other (income) expense, net | 995 | 17 | | 507 | 524 | 471 |
| Income Before Taxes | 2,354 | (5,812) | (1,632) | (507) | (7,951) | 10,305 |
| Taxes on Income | 872 | | | | (1,384) ⁽⁴⁾ | 2,256 |
| Net Income | 1,482 | | | | (6,567) | 8,049 |
| Less: Net Income Attributable to Noncontrolling Interests | 89 | | | | - | 89 |
| Net Income Attributable to Merck & Co., Inc. | \$ 1,393 | | | | \$ (6,567) | \$ 7,960 |
| Earnings per Common Share Assuming Dilution | \$ 0.44 | | | | | \$ 2.54 ⁽⁵⁾ |
| Average Shares Outstanding Assuming Dilution | 3,123 | | | | | 3,123 |
| Tax Rate | 37.1% | | | | | 21.9% |

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of the merger. Amounts included in marketing and administrative expenses and other (income) expense, net reflect transaction and integration costs associated with mergers and acquisitions. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be sold or closed related to actions under the company's formal restructuring programs.

(3) Included in other (income) expense, net is a \$950 million legal reserve and \$443 million of income recognized upon AstraZeneca's asset option exercise.

(4) Includes a \$380 million tax benefit from changes in a foreign entity's tax rate, a charge of \$147 million associated with a change in tax law enacted as part of U.S. health care reform legislation, as well as the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was \$7,927 million for the nine months ended September 30, 2010.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)

Table 3

| | 2011 | | | | 2010 | | | | | | % Change | % Change |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------|------------|
| | 1Q | 2Q | 3Q | Sep YTD | 1Q | 2Q | 3Q | Sep YTD | 4Q | Full Year | 3Q | Sep YTD |
| TOTAL SALES ⁽¹⁾ | \$11,580 | \$12,151 | \$12,022 | \$35,753 | \$11,422 | \$11,346 | \$11,125 | \$33,893 | \$12,094 | \$45,987 | 8 | 5 |
| PHARMACEUTICAL ⁽²⁾ | 9,820 | 10,360 | 10,354 | 30,534 | 9,665 | 9,638 | 9,523 | 28,826 | 10,441 | 39,267 | 9 | 6 |
| Cardiovascular | | | | | | | | | | | | |
| Zetia | 582 | 592 | 614 | 1,788 | 534 | 564 | 571 | 1,668 | 629 | 2,297 | 8 | 7 |
| Vytorin | 480 | 459 | 469 | 1,407 | 477 | 490 | 485 | 1,452 | 562 | 2,014 | -3 | -3 |
| Integrilin | 64 | 56 | 53 | 172 | 70 | 70 | 63 | 203 | 63 | 266 | -16 | -15 |
| Diabetes & Obesity | | | | | | | | | | | | |
| Januvia | 739 | 779 | 846 | 2,364 | 511 | 600 | 600 | 1,710 | 675 | 2,385 | 41 | 38 |
| Janumet | 305 | 321 | 350 | 977 | 201 | 218 | 247 | 666 | 288 | 954 | 42 | 47 |
| Diversified Brands | | | | | | | | | | | | |
| Cozaar / Hyzaar | 426 | 406 | 404 | 1,236 | 782 | 485 | 423 | 1,690 | 415 | 2,104 | -4 | -27 |
| Zocor | 127 | 107 | 110 | 345 | 116 | 117 | 114 | 347 | 121 | 468 | -3 | -1 |
| Propecia | 106 | 112 | 112 | 330 | 100 | 113 | 109 | 322 | 124 | 447 | 2 | 2 |
| Claritin Rx | 120 | 65 | 55 | 240 | 98 | 58 | 53 | 210 | 86 | 296 | 3 | 15 |
| Remeron | 60 | 57 | 65 | 181 | 51 | 59 | 50 | 160 | 62 | 223 | 29 | 13 |
| Vasotec / Vaseretic | 57 | 59 | 57 | 173 | 59 | 63 | 69 | 191 | 64 | 255 | -18 | -10 |
| Proscar | 60 | 53 | 58 | 171 | 58 | 56 | 58 | 172 | 44 | 216 | -- | -1 |
| Infectious Disease | | | | | | | | | | | | |
| Isentress | 292 | 337 | 343 | 972 | 232 | 267 | 278 | 777 | 313 | 1,090 | 23 | 25 |
| PegIntron | 166 | 154 | 163 | 482 | 186 | 185 | 168 | 539 | 198 | 737 | -3 | -11 |
| Candida | 158 | 168 | 150 | 476 | 153 | 150 | 135 | 437 | 174 | 611 | 11 | 9 |
| Primaxin | 136 | 136 | 124 | 397 | 159 | 158 | 135 | 452 | 158 | 610 | -8 | -12 |
| Invanz | 87 | 103 | 107 | 296 | 75 | 83 | 91 | 249 | 113 | 362 | 17 | 19 |
| Avelox | 106 | 61 | 59 | 227 | 106 | 59 | 59 | 224 | 92 | 316 | 1 | 1 |
| Noxafil | 55 | 56 | 61 | 171 | 49 | 50 | 52 | 150 | 48 | 198 | 17 | 14 |
| Crixivan / Stocrin | 45 | 50 | 56 | 151 | 52 | 48 | 49 | 148 | 58 | 206 | 16 | 2 |
| Rebetol | 53 | 48 | 38 | 138 | 56 | 55 | 55 | 166 | 54 | 221 | -32 | -17 |
| Victrelis | 1 | 21 | 31 | 53 | 0 | 0 | 0 | 0 | 0 | 0 | * | * |
| Neurosciences & Ophthalmology | | | | | | | | | | | | |
| Maxalt | 173 | 131 | 156 | 460 | 135 | 133 | 133 | 401 | 149 | 550 | 17 | 15 |
| Cosopt / Trusopt | 114 | 122 | 124 | 360 | 115 | 123 | 114 | 353 | 131 | 484 | 9 | 2 |
| Oncology | | | | | | | | | | | | |
| Temodar | 248 | 234 | 223 | 704 | 274 | 271 | 254 | 799 | 266 | 1,065 | -12 | -12 |
| Emend | 87 | 120 | 98 | 305 | 84 | 93 | 91 | 268 | 110 | 378 | 8 | 14 |
| Intron A | 49 | 47 | 47 | 143 | 54 | 51 | 50 | 155 | 54 | 209 | -6 | -8 |
| Respiratory & Immunology | | | | | | | | | | | | |
| Singular | 1,328 | 1,354 | 1,336 | 4,018 | 1,165 | 1,258 | 1,215 | 3,638 | 1,349 | 4,987 | 10 | 10 |
| Remicade | 753 | 842 | 561 | 2,156 | 674 | 669 | 661 | 2,004 | 710 | 2,714 | -15 | 8 |
| Nasonex | 373 | 323 | 266 | 962 | 320 | 338 | 259 | 917 | 303 | 1,219 | 3 | 5 |
| Clarinex | 155 | 209 | 128 | 492 | 164 | 191 | 131 | 486 | 138 | 623 | -2 | 1 |
| Arcoxia | 114 | 100 | 108 | 321 | 95 | 95 | 94 | 284 | 115 | 398 | 15 | 13 |
| Simponi | 54 | 75 | 74 | 203 | 10 | 18 | 27 | 55 | 42 | 97 | * | * |
| Asmanex | 60 | 47 | 42 | 149 | 51 | 56 | 48 | 155 | 53 | 208 | -12 | -4 |
| Proventil | 42 | 37 | 38 | 117 | 57 | 55 | 43 | 155 | 55 | 210 | -12 | -24 |
| Dulera | 13 | 25 | 22 | 59 | 0 | 0 | 2 | 2 | 6 | 8 | * | * |
| Vaccines | | | | | | | | | | | | |
| Gardasil | 214 | 277 | 445 | 935 | 233 | 219 | 316 | 768 | 221 | 988 | 41 | 22 |
| ProQuad, M-M-R II and Varivax | 244 | 291 | 391 | 927 | 319 | 340 | 434 | 1,093 | 285 | 1,378 | -10 | -15 |
| RotaTeq | 125 | 148 | 184 | 457 | 93 | 139 | 119 | 350 | 169 | 519 | 55 | 31 |
| Pneumovax | 79 | 64 | 133 | 276 | 51 | 59 | 110 | 220 | 156 | 376 | 21 | 25 |
| Zostavax | 24 | 122 | 108 | 254 | 95 | 18 | 23 | 136 | 107 | 243 | * | 86 |
| Women's Health & Endocrine | | | | | | | | | | | | |
| Fosamax | 208 | 221 | 215 | 644 | 230 | 241 | 220 | 692 | 234 | 926 | -2 | -7 |
| NuvaRing | 142 | 154 | 159 | 455 | 135 | 145 | 134 | 414 | 145 | 559 | 18 | 10 |
| Follistim AQ | 133 | 143 | 129 | 404 | 134 | 137 | 119 | 389 | 138 | 528 | 8 | 4 |
| Implanon | 60 | 81 | 80 | 220 | 51 | 51 | 64 | 165 | 71 | 236 | 25 | 34 |
| Cerazette | 59 | 66 | 74 | 199 | 55 | 49 | 56 | 160 | 49 | 209 | 32 | 24 |
| Other Pharmaceutical ⁽³⁾ | 744 | 927 | 888 | 2,567 | 946 | 941 | 942 | 2,834 | 1,044 | 3,879 | -6 | -9 |
| ANIMAL HEALTH | 758 | 802 | 826 | 2,385 | 709 | 731 | 687 | 2,126 | 815 | 2,941 | 20 | 12 |
| CONSUMER CARE ⁽²⁾ | 517 | 541 | 421 | 1,479 | 489 | 544 | 409 | 1,442 | 381 | 1,823 | 3 | 3 |
| Claritin OTC | 167 | 134 | 118 | 419 | 136 | 167 | 120 | 423 | 103 | 526 | -2 | -1 |
| Other Revenues ⁽⁴⁾ | 486 | 448 | 421 | 1,355 | 559 | 433 | 506 | 1,499 | 457 | 1,956 | -17 | -10 |
| Astra | 322 | 306 | 299 | 928 | 364 | 241 | 345 | 950 | 302 | 1,252 | -13 | -2 |

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Only select products are shown.⁽²⁾ Beginning in 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.⁽³⁾ Includes pharmaceutical products not individually shown above. Other vaccines sales included in Other Pharmaceutical were \$54 million, \$67 million and \$100 million for the first, second and third quarters of 2011, respectively. Other vaccines sales included in Other Pharmaceutical were \$55 million, \$57 million, \$94 million and \$75 million for the first, second, third and fourth quarters of 2010, respectively.⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2011
(AMOUNTS IN MILLIONS)

Table 3a

| | Global | | | U.S. | | | International | | |
|--|-----------------|-----------------|------------|----------------|----------------|------------|----------------|----------------|-----------|
| | 3Q11 | 3Q10 | % Change | 3Q11 | 3Q10 | % Change | 3Q11 | 3Q10 | % Change |
| TOTAL SALES ⁽¹⁾ | \$12,022 | \$11,125 | 8 | \$5,345 | \$5,139 | 4 | \$6,677 | \$5,985 | 12 |
| PHARMACEUTICAL ⁽²⁾ | 10,354 | 9,523 | 9 | 4,515 | 4,265 | 6 | 5,839 | 5,258 | 11 |
| Cardiovascular | | | | | | | | | |
| Zetia | 614 | 571 | 8 | 306 | 310 | -1 | 308 | 261 | 18 |
| Vytorin | 469 | 485 | -3 | 213 | 263 | -19 | 256 | 222 | 15 |
| Integrilin | 53 | 63 | -16 | 47 | 57 | -17 | 5 | 6 | -7 |
| Diabetes & Obesity | | | | | | | | | |
| Januvia | 846 | 600 | 41 | 473 | 405 | 17 | 373 | 195 | 91 |
| Janumet | 350 | 247 | 42 | 183 | 151 | 21 | 167 | 97 | 73 |
| Diversified Brands | | | | | | | | | |
| Cozaar / Hyzaar | 404 | 423 | -4 | 36 | 37 | -2 | 368 | 386 | -5 |
| Zocor | 110 | 114 | -3 | 7 | 11 | -30 | 103 | 103 | |
| Propecia | 112 | 109 | 2 | 33 | 37 | -10 | 78 | 72 | 8 |
| Claritin Rx | 55 | 53 | 3 | | | | 55 | 53 | 3 |
| Remeron | 65 | 50 | 29 | 1 | 2 | -27 | 63 | 49 | 31 |
| Vasotec / Vaseretic | 57 | 69 | -18 | | | | 57 | 69 | -18 |
| Proscar | 58 | 58 | | 1 | 2 | -23 | 56 | 56 | 1 |
| Infectious Disease | | | | | | | | | |
| Isentress | 343 | 278 | 23 | 168 | 149 | 12 | 175 | 129 | 36 |
| PegIntron | 163 | 168 | -3 | 19 | 12 | 60 | 144 | 157 | -8 |
| Cancidas | 150 | 135 | 11 | 14 | 15 | -7 | 136 | 120 | 14 |
| Primaxin | 124 | 135 | -8 | 21 | 27 | -25 | 103 | 108 | -4 |
| Invanz | 107 | 91 | 17 | 55 | 48 | 13 | 52 | 43 | 22 |
| Avelox | 59 | 59 | 1 | 49 | 54 | -9 | 10 | 5 | * |
| Noxafil | 61 | 52 | 17 | 17 | 15 | 12 | 44 | 37 | 19 |
| Crixivan / Stocrin | 56 | 49 | 16 | 1 | 2 | -37 | 55 | 47 | 18 |
| Rebetol | 38 | 55 | -32 | | 1 | * | 38 | 54 | -31 |
| Victrelis | 31 | | * | 21 | | * | 10 | | * |
| Neurosciences & Ophthalmology | | | | | | | | | |
| Maxalt | 156 | 133 | 17 | 105 | 95 | 10 | 51 | 38 | 34 |
| Cosopt / Trusopt | 124 | 114 | 9 | 4 | 5 | -20 | 121 | 110 | 10 |
| Oncology | | | | | | | | | |
| Temodar | 223 | 254 | -12 | 100 | 98 | 2 | 123 | 156 | -21 |
| Emend | 98 | 91 | 8 | 60 | 60 | | 38 | 31 | 24 |
| Intron A | 47 | 50 | -6 | 23 | 26 | -12 | 24 | 24 | 1 |
| Respiratory & Immunology | | | | | | | | | |
| Singulair | 1,336 | 1,215 | 10 | 901 | 823 | 10 | 435 | 393 | 11 |
| Remicade | 561 | 661 | -15 | | | | 561 | 661 | -15 |
| Nasonex | 266 | 259 | 3 | 135 | 142 | -4 | 130 | 118 | 11 |
| Clarinet | 128 | 131 | -2 | 46 | 47 | -1 | 82 | 84 | -3 |
| Arcoxia | 108 | 94 | 15 | | | | 108 | 94 | 15 |
| Simponi | 74 | 27 | * | | | | 74 | 27 | * |
| Asmanex | 42 | 48 | -12 | 38 | 45 | -16 | 4 | 3 | 61 |
| Proventil | 38 | 43 | -12 | 35 | 41 | -13 | 2 | 2 | -1 |
| Dulera | 22 | 2 | * | 22 | 2 | * | | | |
| Vaccines | | | | | | | | | |
| Gardasil | 445 | 316 | 41 | 330 | 247 | 34 | 115 | 70 | 66 |
| ProQuad, M-M-R II and Varivax | 391 | 434 | -10 | 369 | 414 | -11 | 22 | 21 | 6 |
| RotaTeq | 184 | 119 | 55 | 133 | 99 | 35 | 51 | 20 | * |
| Pneumovax | 133 | 110 | 21 | 107 | 92 | 17 | 26 | 18 | 43 |
| Zostavax | 108 | 23 | * | 105 | 23 | * | 4 | | * |
| Women's Health & Endocrine | | | | | | | | | |
| Fosamax | 215 | 220 | -2 | 10 | 21 | -53 | 205 | 198 | 3 |
| NuvaRing | 159 | 134 | 18 | 90 | 84 | 7 | 68 | 50 | 38 |
| Follistim AQ | 129 | 119 | 8 | 45 | 43 | 5 | 84 | 76 | 10 |
| Implanon | 80 | 64 | 25 | 34 | 24 | 41 | 45 | 39 | 16 |
| Cerazette | 74 | 56 | 32 | | | | 74 | 56 | 32 |
| Other Pharmaceutical ⁽³⁾ | 888 | 942 | -6 | 155 | 239 | -35 | 734 | 703 | 4 |
| ANIMAL HEALTH | 826 | 687 | 20 | 194 | 154 | 26 | 631 | 533 | 18 |
| CONSUMER CARE ⁽²⁾ | 421 | 409 | 3 | 265 | 263 | 1 | 156 | 146 | 7 |
| Claritin OTC | 118 | 120 | -2 | 79 | 87 | -9 | 39 | 33 | 19 |
| Other Revenues ⁽⁴⁾ | 421 | 506 | -17 | 370 | 458 | -19 | 50 | 48 | 4 |
| Astra | 299 | 345 | -13 | 299 | 345 | -13 | | | |

⁽¹⁾ Only select products are shown.

⁽²⁾ In the first quarter of 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.

⁽³⁾ Includes Pharmaceutical products not individually shown above. Other Vaccine sales included in Other Pharmaceutical were \$100 million and \$94 million on a global basis for third quarter 2011 and 2010 respectively.

⁽⁴⁾ Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2011
(AMOUNTS IN MILLIONS)

Table 3b

| | Global | | | U.S. | | | International | | |
|---|-----------------|-----------------|------------|-----------------|-----------------|------------|-----------------|-----------------|------------|
| | Sep YTD 2011 | Sep YTD 2010 | % Change | Sep YTD 2011 | Sep YTD 2010 | % Change | Sep YTD 2011 | Sep YTD 2010 | % Change |
| TOTAL SALES⁽¹⁾ | \$35,753 | \$33,893 | 5 | \$15,199 | \$15,001 | 1 | \$20,554 | \$18,892 | 9 |
| PHARMACEUTICAL⁽²⁾ | 30,534 | 28,826 | 6 | 12,511 | 12,364 | 1 | 18,023 | 16,462 | 9 |
| Cardiovascular | | | | | | | | | |
| Zetia | 1,788 | 1,668 | 7 | 896 | 898 | | 892 | 770 | 16 |
| Vytorin | 1,407 | 1,452 | -3 | 675 | 781 | -14 | 733 | 671 | 9 |
| Integrilin | 172 | 203 | -15 | 158 | 188 | -16 | 15 | 15 | -1 |
| Diabetes & Obesity | | | | | | | | | |
| Januvia | 2,364 | 1,710 | 38 | 1,322 | 1,138 | 16 | 1,042 | 572 | 82 |
| Janumet | 977 | 666 | 47 | 518 | 412 | 26 | 458 | 255 | 80 |
| Diversified Brands | | | | | | | | | |
| Cozaar / Hyzaar | 1,236 | 1,690 | -27 | 87 | 391 | -78 | 1,149 | 1,298 | -12 |
| Zocor | 345 | 347 | -1 | 24 | 30 | -18 | 320 | 318 | 1 |
| Propecia | 330 | 322 | 2 | 98 | 109 | -10 | 232 | 213 | 9 |
| Claritin Rx | 240 | 210 | 15 | | | | 240 | 210 | 15 |
| Remeron | 181 | 160 | 13 | 5 | 5 | -8 | 176 | 155 | 14 |
| Vasotec / Vaseretic | 173 | 191 | -10 | | | | 173 | 191 | -10 |
| Proscar | 171 | 172 | -1 | 4 | 5 | -24 | 167 | 167 | |
| Infectious Disease | | | | | | | | | |
| Isentress | 972 | 777 | 25 | 488 | 391 | 25 | 484 | 386 | 25 |
| PegIntron | 482 | 539 | -11 | 46 | 63 | -27 | 436 | 477 | -8 |
| Cancidas | 476 | 437 | 9 | 32 | 44 | -27 | 443 | 393 | 13 |
| Primaxin | 397 | 452 | -12 | 72 | 95 | -24 | 324 | 357 | -9 |
| Invanz | 296 | 249 | 19 | 150 | 130 | 16 | 146 | 119 | 23 |
| Avelox | 227 | 224 | 1 | 201 | 210 | -4 | 25 | 14 | 82 |
| Noxafil | 171 | 150 | 14 | 44 | 42 | 6 | 127 | 109 | 17 |
| Crixivan / Stocrin | 151 | 148 | 2 | 4 | 6 | -33 | 147 | 142 | 3 |
| Rebetol | 138 | 166 | -17 | 1 | 1 | -24 | 137 | 165 | -17 |
| Victrelis | 53 | | * | 39 | | * | 14 | | * |
| Neurosciences & Ophthalmology | | | | | | | | | |
| Maxalt | 460 | 401 | 15 | 319 | 271 | 18 | 141 | 130 | 9 |
| Cosopt / Trusopt | 360 | 353 | 2 | 12 | 15 | -16 | 348 | 338 | 3 |
| Oncology | | | | | | | | | |
| Temodar | 704 | 799 | -12 | 298 | 293 | 1 | 407 | 505 | -20 |
| Emend | 305 | 268 | 14 | 171 | 166 | 3 | 134 | 102 | 31 |
| Intron A | 143 | 155 | -8 | 72 | 86 | -16 | 71 | 70 | 2 |
| Respiratory & Immunology | | | | | | | | | |
| Singular | 4,018 | 3,638 | 10 | 2,579 | 2,381 | 8 | 1,439 | 1,257 | 14 |
| Remicade | 2,156 | 2,004 | 8 | | | | 2,156 | 2,004 | 8 |
| Nasonex | 962 | 917 | 5 | 440 | 493 | -11 | 521 | 424 | 23 |
| Clarinex | 492 | 486 | 1 | 146 | 155 | -6 | 347 | 330 | 5 |
| Arcoxia | 321 | 284 | 13 | | | | 321 | 284 | 13 |
| Simponi | 203 | 55 | * | | | | 203 | 55 | * |
| Asmanex | 149 | 155 | -4 | 134 | 148 | -10 | 15 | 7 | * |
| Proventil | 117 | 155 | -24 | 111 | 149 | -26 | 7 | 6 | 15 |
| Dulera | 59 | 2 | * | 58 | 2 | * | 1 | | * |
| Vaccines | | | | | | | | | |
| Gardasil | 935 | 768 | 22 | 679 | 565 | 20 | 256 | 202 | 27 |
| ProQuad, M-M-R II and Varivax | 927 | 1,093 | -15 | 865 | 1,033 | -16 | 62 | 61 | 2 |
| RotaTeq | 457 | 350 | 31 | 360 | 290 | 24 | 96 | 60 | 61 |
| Pneumovax | 276 | 220 | 25 | 214 | 181 | 18 | 62 | 40 | 57 |
| Zostavax | 254 | 136 | 86 | 247 | 136 | 81 | 7 | | * |
| Women's Health & Endocrine | | | | | | | | | |
| Fosamax | 644 | 692 | -7 | 38 | 68 | -45 | 606 | 623 | -3 |
| NuvaRing | 455 | 414 | 10 | 267 | 255 | 4 | 188 | 159 | 19 |
| Follistim AQ | 404 | 389 | 4 | 121 | 127 | -4 | 283 | 263 | 8 |
| Implanon | 220 | 165 | 34 | 92 | 62 | 48 | 128 | 103 | 25 |
| Cerazette | 199 | 160 | 24 | | | | 199 | 160 | 24 |
| Other Pharmaceutical⁽³⁾ | 2,567 | 2,834 | -9 | 424 | 550 | -23 | 2,144 | 2,284 | -6 |
| ANIMAL HEALTH | 2,385 | 2,126 | 12 | 519 | 446 | 16 | 1,867 | 1,680 | 11 |
| CONSUMER CARE⁽²⁾ | 1,479 | 1,442 | 3 | 986 | 981 | 5 | 493 | 460 | 7 |
| Claritin OTC | 419 | 423 | -1 | 304 | 313 | -3 | 115 | 109 | 5 |
| Other Revenues⁽⁴⁾ | 1,355 | 1,499 | -10 | 1,184 | 1,211 | -2 | 172 | 288 | -40 |
| Astra | 928 | 950 | -2 | 928 | 950 | -2 | | | |

(1) Only select products are shown.

(2) In the first quarter of 2011, Merck changed the reporting for certain over-the-counter products. Sales of these products outside the United States were previously recorded in the Pharmaceutical business, and are now reported in the Consumer Care business. Prior period amounts have been recast on a comparative basis.

(3) Includes Pharmaceutical products not individually shown above. Other Vaccine sales included in Other Pharmaceutical were \$221 million and \$207 million on a global basis for September YTD 2011 and 2010 respectively.

(4) Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)

Table 3c

| | 1Q11 | 2Q11 | 3Q11 | Sep YTD 11 | 1Q10 | 2Q10 | 3Q10 | Sep YTD 10 | 4Q10 | Full Year | % Change 3Q | % Change YTD |
|--|----------------|-----------------|-----------------|-----------------|----------------|----------------|----------------|-----------------|-----------------|-----------------|-------------------|--------------------|
| TOTAL PHARMACEUTICAL | \$9,820 | \$10,360 | \$10,354 | \$30,534 | \$9,665 | \$9,638 | \$9,523 | \$28,826 | \$10,441 | \$39,267 | 9 | 6 |
| United States | 3,907 | 4,088 | 4,515 | 12,511 | 4,072 | 4,026 | 4,265 | 12,364 | 4,384 | 16,748 | 6 | 1 |
| % Pharmaceutical Sales | 39.8% | 39.5% | 43.6% | 41.0% | 42.1% | 41.8% | 44.8% | 42.9% | 42.0% | 42.7% | | |
| Europe ⁽¹⁾ | 2,587 | 2,827 | 2,588 | 8,002 | 2,810 | 2,631 | 2,342 | 7,782 | 2,677 | 10,459 | 11 | 3 |
| % Pharmaceutical Sales | 26.3% | 27.3% | 25.0% | 26.2% | 29.1% | 27.3% | 24.6% | 27.0% | 25.6% | 26.6% | | |
| Japan | 1,164 | 1,104 | 1,114 | 3,382 | 811 | 902 | 855 | 2,568 | 1,077 | 3,645 | 30 | 32 |
| % Pharmaceutical Sales | 11.8% | 10.7% | 10.8% | 11.1% | 8.4% | 9.4% | 9.0% | 8.9% | 10.3% | 9.3% | | |
| Latin America | 700 | 743 | 667 | 2,109 | 659 | 696 | 699 | 2,054 | 778 | 2,832 | -5 | 3 |
| % Pharmaceutical Sales | 7.1% | 7.2% | 6.4% | 6.9% | 6.8% | 7.2% | 7.3% | 7.1% | 7.5% | 7.2% | | |
| Asia Pacific | 699 | 779 | 763 | 2,241 | 561 | 622 | 618 | 1,801 | 702 | 2,503 | 23 | 24 |
| % Pharmaceutical Sales | 7.1% | 7.5% | 7.4% | 7.3% | 5.8% | 6.5% | 6.5% | 6.2% | 6.7% | 6.4% | | |
| China | 187 | 206 | 220 | 613 | 133 | 159 | 145 | 437 | 173 | 611 | 52 | 40 |
| Eastern Europe/Middle East Africa | 358 | 369 | 371 | 1,097 | 375 | 395 | 353 | 1,123 | 393 | 1,516 | 5 | -2 |
| % Pharmaceutical Sales | 3.6% | 3.6% | 3.6% | 3.6% | 3.9% | 4.1% | 3.7% | 3.9% | 3.8% | 3.9% | | |
| Canada | 360 | 399 | 285 | 1,044 | 337 | 328 | 374 | 1,039 | 364 | 1,403 | -24 | 0 |
| % Pharmaceutical Sales | 3.7% | 3.9% | 2.8% | 3.4% | 3.5% | 3.4% | 3.9% | 3.6% | 3.5% | 3.6% | | |
| Other | 45 | 51 | 51 | 147 | 40 | 37 | 17 | 94 | 67 | 161 | * | 56 |
| % Pharmaceutical Sales | 0.5% | 0.5% | 0.5% | 0.5% | 0.4% | 0.4% | 0.2% | 0.3% | 0.6% | 0.4% | | |

* 100% or over

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.
EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE - GAAP
THIRD QUARTER 2011
AMOUNTS IN MILLIONS

Table 4

EQUITY INCOME FROM AFFILIATES

| | 3Q11 | 3Q10 | Sep YTD 2011 | Sep YTD 2010 |
|----------------------|---------------|---------------|-----------------|-----------------|
| ASTRAZENECA LP | \$ 141 | \$ 192 | \$ 318 | \$ 357 |
| Other ⁽¹⁾ | 20 | 44 | 36 | 60 |
| TOTAL | \$ 161 | \$ 236 | \$ 354 | \$ 417 |

⁽¹⁾ Primarily reflects results for Sanofi Pasteur MSD and Johnson & Johnson^oMerck Consumer Pharmaceuticals ("JIMCP"). In the third quarter of 2011, the company divested its interest in the JIMCP joint venture .

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a "NET" basis.

| | 3Q11 | 3Q10 | Sep YTD 2011 | Sep YTD 2010 |
|---------------------------------------|---------------|---------------|-----------------|-----------------|
| GARDASIL | \$ 59 | \$ 79 | \$ 183 | \$ 244 |
| FLU VACCINES | 128 | 148 | 129 | 158 |
| OTHER VIRAL VACCINES | 29 | 20 | 77 | 66 |
| ROTATEQ | 12 | 8 | 32 | 33 |
| HEPATITIS VACCINES | 9 | 6 | 29 | 18 |
| Other Vaccines | 138 | 121 | 355 | 352 |
| TOTAL SANOFI PASTEUR MSD SALES | \$ 375 | \$ 382 | \$ 805 | \$ 871 |

OTHER (INCOME) EXPENSE, NET

| | 3Q11 | 3Q10 | Sep YTD 2011 | Sep YTD 2010 |
|---------------------------|--------------|-----------------|-----------------|-----------------|
| INTEREST INCOME | \$ (45) | \$ (23) | \$ (137) | \$ (57) |
| INTEREST EXPENSE | 189 | 173 | 557 | 539 |
| EXCHANGE LOSSES | 59 | 8 | 102 | 84 |
| Other, net ⁽¹⁾ | (137) | 950 | 287 | 429 |
| TOTAL | \$ 66 | \$ 1,108 | \$ 809 | \$ 995 |

⁽¹⁾ Other, net in the first nine months of 2011 includes a charge of \$500 million related to the resolution of the arbitration proceeding with Johnson & Johnson. Other, net in the third quarter and first nine months of 2010 reflects a \$950 million legal reserve. Other, net in the first nine months of 2010 also includes \$443 million of income recognized upon AstraZeneca's asset option exercise.